Abstract
Monoclonal gammopathy of renal significance (MGRS) is a pathogenic entity associated with significant morbidity, mainly end stage kidney disease. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), a type of MGRS, is a specific disease resulting from the deposition of a monoclonal immunoglobulin leading to kidney damage. While PGNMID has been recognized to lead to end-stage kidney disease, until recently there was no evidence to guide treatment. Here, we report a case of a patient with PGNMID who responded well to daratumumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
